Clinical Trials Browser

Phase 2 × OTHER × Afatinib × Clear all

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT04497584 2025-10-01

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Phase 2 Active not recruiting

Advanced Squamous Non Small Cell Lung Cancer

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05215548 2025-02-19

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Phase 2 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT01553942 2024-11-20

Afatinib With CT and RT for EGFR-Mutant NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT04839471 2024-07-08

BEAR

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04410653 2024-04-05

Afatinib in Advanced NRG1-Rearranged Malignancies

Phase 2 Completed

Neoplasm Metastasis

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01522768 2023-11-01

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Phase 2 Completed

42 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02506517 2023-08-01

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Phase 2 Completed

Other solid neoplasm

Solid Tumors

NCT05865132 2023-05-18

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Phase 2 Unknown

PFS

NCT02501603 2023-01-27

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04201756 2022-12-23

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Phase 2 Completed

Adenocarcinoma of Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01320280 2022-07-01

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Phase 2 Terminated

Neoplasms, Prostatic Neoplasms

NCT03695510 2022-04-21

ALPHA

Phase 2 Completed

Head and Neck Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT01415674 2022-02-02

PREDICTOR

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02629523 2021-08-03

LiquidLung-A

Phase 2 Completed

Lung Neoplasms

NCT04880811 2021-07-13

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04533321 2020-08-31

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Phase 2 Unknown

Carcinoma, Squamous Cell

NCT01746251 2020-07-07

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02595840 2019-04-19

Trans-MARBLE

Phase 2 Terminated

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT02353936 2019-02-11

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03810872 2019-01-22

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Phase 2 Unknown

SarcomaThoracic

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01919879 2018-05-08

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02488694 2018-01-09

MARBLE

Phase 2 Terminated

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02876081 2017-09-11

THEN

Phase 2 Withdrawn

Small Cell Lung Carcinoma

NCT01728818 2017-07-19

ACCEPT

Phase 2 Unknown

Focus of Study Instead

NCT02274012 2017-03-14

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Phase 2 Withdrawn

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01480141 2013-03-26

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Lung Neoplasms